Recommendations made out-of-session by the PBAC between meetings
Page last updated: 14 July 2023
Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) out-of-session between its ordinary meetings (March, July and November) and Intracycle meetings relating to the listing of drugs on the Pharmaceutical Benefits Scheme (PBS). Public Summary Documents (PSDs) relating to PBAC recommendations made out-of-session between its ordinary and Intracycle meetings are published with the PSDs for the next ordinary meeting, except where it is practical and reasonable to add an addendum to the PSD relating to the PBAC’s last consideration of the matter.
- Recommendations made between March 2019 and November 2019 PBAC meetings (PDF 46KB) – (Word 51KB)
- Recommendations made between July 2020 and September 2020 PBAC meetings (PDF 37KB) – (Word 20KB)
- Recommendations made between July 2020 and November 2020 PBAC meetings (PDF 37KB) – (Word 20KB)
- Recommendations made between November 2020 and March 2021 PBAC meetings (PDF 37KB) – (Word 20KB)
- Recommendations made between March 2021 and July 2021 PBAC meetings (PDF 182KB) – (Word 20KB)
- Recommendations made between July 2021 and November 2021 PBAC meetings (PDF 280KB) – (Word 19KB)
- PBAC Recommendation for molnupiravir (Lagevrio®) February 2022 (PDF 108KB) - (Word 53KB)
- PBAC Recommendation for nirmatrelvir and ritonavir (Paxlovid®) March 2022 (PDF 104KB) - (Word 37KB)
- PBAC Recommendation for amendments to COVID-19 oral treatment restrictions June 2022 (PDF 133KB) – (Word 21KB)
- Recommendations made between July 2022 and November 2022 PBAC meetings (PDF 83KB) – (Word 25KB)
- Recommendations made between November 2022 and March 2023 PBAC meetings (PDF 143KB) – (Word 55KB)
- Recommendations made between March 2023 and July 2023 PBAC meetings (PDF 184KB) – (Word 56KB)
